

The Use of Hyperbaric Oxygen Therapy in Ophthalmic Practice

Essay

*Submitted For Partial Fulfillment of Masters Degree
in Ophthalmology*

By

Ahmed Zaki Wahba Ismail

M.B, B.Ch

Supervised By

Prof. Dr. Sherif Zaky Mansour

Professor of Ophthalmology

Faculty of Medicine, Ain Shams University

Assistant.Prof.Dr.Thanaa Helmy Mohammed

Assistant Professor of Ophthalmology

Faculty of Medicine, Ain Shams University

Dr. Nancy Ezz El Regal Khamis

Lecturer of Ophthalmology

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

Cairo, Egypt

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم
سورة النساء آية (١١٣)



*First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Sherif Zaky Mansour**, Professor of Ophthalmology Faculty of Medicine, Ain Shams University for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Assistant Prof. Dr. Thanaa Helmy Mohammed**, Assistant Professor of Ophthalmology Faculty of Medicine, Ain Shams University for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Maney Ezz El Regal Khamis**, Lecturer of Ophthalmology Faculty of Medicine, Ain Shams University for her great help, outstanding support, active participation and guidance.*

Ahmed Zaki Wahba

List of Contents

Title	Page No.
List of Abbreviations	5
List of Tables	5i
List of Figures	7i
Introduction	1
Aim of the Work	3
History and Development of Hyperbaric Oxygen	4
Physiological Basis of Hyperbaric Oxygen Therapy	6
Types of oxygen Chambers	14
Hyperbaric Oxygen Therapy (HBOT) General Considerations	17
Indications for HBO Therapy in Ocular Diseases	22
Side Effects of Hyperbaric Oxygen Therapy	76
Summary	81
Conclusion	83
References	84
Arabic Summary	

List of Abbreviations

<i>Abb.</i>	<i>Full term</i>
<i>AGE</i>	<i>Arterial gas embolism</i>
<i>AMD</i>	<i>Age-related macular degeneration</i>
<i>ATA</i>	<i>Atmospheres absolute</i>
<i>BID</i>	<i>Bis in die</i>
<i>CO</i>	<i>Carbon monoxide</i>
<i>CRAO</i>	<i>Central retinal artery occlusion</i>
<i>DCS</i>	<i>Decompression sickness</i>
<i>ERG</i>	<i>Electroretinographic</i>
<i>FDA</i>	<i>Food and drug administration</i>
<i>HBO</i>	<i>Hyperbaric oxygen therapy</i>
<i>ICP</i>	<i>Intracranial pressure</i>
<i>IL-10</i>	<i>Interleukin-10</i>
<i>NO</i>	<i>Nitric oxide</i>
<i>RK</i>	<i>Radial keratotomy</i>
<i>ROS</i>	<i>Reactive oxygen species</i>
<i>TNF-α</i>	<i>Tumor necrosis factor-α</i>
<i>TVF</i>	<i>Temporal visual field</i>
<i>UHMS</i>	<i>Undersea and Hyperbaric Medical Society</i>
<i>UMS</i>	<i>Undersea Medical Society</i>

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison of Monoplace and Multiplace Hyperbaric Oxygen Chambers. ⁽⁴³⁾	16
Table (2):	Indications of HBOT in ocular diseases. ⁽⁵²⁾	22
Table (3):	Treatment of retinal artery occlusions: literature summary.....	41

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Cunningham's device	4
Figure (2):	Monoplace HBOT chamber	14
Figure (3):	Multiplace HBOT chamber	15
Figure (4):	CRAO with cherry-red spot	28
Figure (5):	A 47-year-old man with mucormycosis	44
Figure (6):	Left cornea two weeks after infection	48
Figure (7):	Left cornea six weeks after infection and after treatment with HBO.....	49
Figure (8):	Age related macular degeneration fundus.....	49
Figure (9):	Optical coherence tomography retinal color map (top) and thickness map (bottom) showing central macular thickness before any treatment.....	54
Figure (10):	OCT color retinal map (top) and thickness map (bottom) after treatment	55
Figure (11):	Late phase fluorescein angiography.....	55
Figure (12):	OCT demonstrates cystoid macular edema	58
Figure (13):	Scleral melting.	60
Figure (14):	Radiation optic neuropathy	63
Figure (15):	Retinitis pigmentosa fundus	65
Figure (16):	Diabetic retinopathy	67
Figure (17):	By HBO significantly reduced blind spot area remained stable for 3 months.....	71

List of Figures cont...

Fig. No.	Title	Page No.
Figure (18):	By HBO significantly improved visual field remained stable for 3 months, except 1.e. I3, and I4 Proved.....	72
Figure (19):	(A) Initial fluorescein angiography of the left eye showed a large area of capillary dropout at the macula and late-phase vessel leakage; (B) color fundus revealed scattered retinal hemorrhage with multiple patches of retinal lesions.	74
Figure (20):	(A) Follow-up fluorescein angiography of the left eye 1 month after hyperbaric oxygen therapy; (B) the left eye macular ischemia persisted, but had improved	74

Abstract

Background: Hyperbaric oxygen therapy is now considered a recognized primary or adjuvant therapeutic technique used in treatment of many acute and chronic diseases. Currently, eye diseases are among the promising use of hyperbaric oxygen however there is increasing evidence showing its safety and efficacy in central retinal artery occlusion, cystoid macular edema secondary to retinal vein occlusion, scleral thinning and necrosis faced after pterygium surgery, orbital rhino-cerebral mucormycosis, non-healing corneal edema, anterior segment ischemia, and diabetic retinopathy.

Objectives: The aim of the study is to evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in treatment of some ophthalmological disorders.

Key words: Hyperbaric oxygen therapy - Atmospheres absolute - Central retinal artery occlusion – Retinitis pigmentosa.

INTRODUCTION

Hyperbaric oxygen therapy (HBOT) is defined by the Undersea and Hyperbaric Medical Society (UHMS) as a treatment in which a patient intermittently breathes 100% oxygen while the treatment chamber is pressurized to a pressure greater than sea level (1 atmosphere absolute, ATA). The pressure increase must be systemic, and may be applied in monoplace (single person) or multiplace chambers. Multiplace chambers are pressurized with air, with oxygen given via face-mask, hood tent or endotracheal tube; while monoplace chambers are pressurized with oxygen.⁽¹⁾

HBOT is considered a recognized primary or adjuvant therapeutic method used in treatment of various acute and chronic diseases. Eye diseases are among the off-label use of hyperbaric oxygen. However, there is an increasing body of evidence showing its safety and efficacy in central retinal artery occlusion, cystoid macular edema secondary to retinal vein occlusion, scleral thinning and necrosis faced after pterygium surgery, orbital rhino-cerebral mucormucosis, non-healing corneal edema, anterior segment ischemia, and diabetic retinopathy.⁽²⁾

HBOT is largely safe when properly administered, although the potential systemic and ocular complications are carefully described. The principal systemic complications are pulmonary, central nervous system and hypertensive effects.

The ocular complications include progressive (but reversible) myopia with repeated treatment sessions, and cataract. The only absolute ocular contraindication to HBOT is the presence of an intraocular gas bubble due to prior surgery or trauma.⁽³⁾

There is a growing interest in the use of HBOT in medicine in general, and in ophthalmology in particular. The indications for its use have become clearer, and newer indications have appeared in the literature. The number of HBOT-cabins available throughout the world continues to increase.

AIM OF THE STUDY

The aim of this work is to review literature about basic principles of hyperbaric oxygen therapy and its different uses in ophthalmic practice.

HISTORY AND DEVELOPMENT OF HYPERBARIC OXYGEN

Hyperbaric oxygen therapy(HBO) was first documented in 1662, when a British physician called Henshaw built the first hyperbaric chamber, or ‘domicilium’. Since this time, reports of beneficial effects from increased pressure have increased, and by 1877, chambers were used widely for many conditions, though there was little scientific rationale or evidence. In 1879, the surgical application of hyperbaric therapy in prolonging safe anaesthesia was realized and explored.⁽⁴⁾

In 1927, Dr Cunningham, a professor of anesthesia reported improvement in circulatory disorders at sea level and deterioration at altitude, and a patient who was grateful to Cunningham for his recovery after HBO treatment, built the huge ‘steel ball hospital’ chamber, but this was closed when Cunningham failed to produce evidence for its use.⁽⁵⁾




Figure (1): Cunningham’s giant steel ball hyperbaric chamber built in 1928 in Cleveland, Ohio.⁽⁶⁾

The advent of the use of HBO in modern clinical medicine began in 1955 with the work of Churchill-Davis, who helped to attenuate the effects of radiation therapy in cancer patients using high-oxygen environments.

That same year, Dr Boerma, a professor of surgery at the University of Amsterdam in Holland, proposed using hyperbaric oxygen (HBO) in cardiac surgery to help prolong the patient's tolerance to circulatory arrest. He conducted surgical operations under pressure, including surgical correction of transposition of the great vessels, tetralogy of Fallot and pulmonic stenosis.⁽⁷⁾

It is frequently said that the history of "hyperbaric oxygenation" goes back "over 300 years," probably referring to the work of Henshaw. This is incorrect, in that oxygen was not discovered until 1775 by Joseph Priestly. All the early chambers were pressurized with compressed air, and oxygen was not a consideration.

Clinical hyperbaric oxygen goes back only about 55 years, beginning with the work of Churchill-Davidson and Boerma.⁽⁸⁾

In 1967 the Undersea Medical Society (UMS) was founded by six U.S. Navy Diving and Submarine medical officers as an organization dedicated to diving and undersea medicine. The UMS was later renamed Undersea and Hyperbaric Medical Society (UHMS) in 1986. This professional society was established for those practicing hyperbaric medicine or diving medicine. They are responsible for publishing approved indication for HBOT.⁽⁹⁾

PHYSIOLOGICAL BASIS OF HYPERBARIC OXYGEN THERAPY

Physics of Hyperbaric Medicine:

The effects of HBO are based on the gas laws, and the physiological and biochemical effects of hyperoxia.⁽¹⁰⁾

Boyle's law states that at a constant temperature, the pressure and volume of a gas are inversely proportional. This is the basis for many aspects of hyperbaric therapy, including a slight increase in chamber temperature during treatment, and the phenomenon known as 'squeeze', occurring when blocked eustachian tubes prevent equalization of gas pressure, resulting in painful compression of gas in the middle ear. In patients who cannot independently achieve pressure equalization, the placement of tympanostomy tubes should be considered to provide a channel between the inner and outer ear air spaces. Similarly, trapped gas can enlarge dangerously during decompression, such as in the rare example of a pneumothorax occurring at pressure.⁽¹¹⁾

Dalton's law states that in a mixed gas each element exerts a pressure proportional to its fraction of the total volume (partial pressure).⁽¹²⁾

Henry's law states that the amount of gas dissolved in a liquid or tissue is proportional to the partial pressure of that gas in contact with the liquid or tissue. This is the basis for